By Counterforce Health Team in Photrexa (riboflavin ophthalmic solution) —

How to Get Photrexa Covered by Cigna in Illinois: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Photrexa Covered by Cigna in Illinois

Cigna covers Photrexa (riboflavin ophthalmic solution) for progressive keratoconus with prior authorization. Submit PA through your ophthalmologist with documented progression (≥1.0 D Kmax increase over 12-24 months), serial topography, and medical necessity letter. If denied, file internal appeal within 180 days, then Illinois external review within 30 days of final denial.

First step today: Call Cigna member services (number on your ID card) to confirm PA requirements and verify your ophthalmologist is in-network for corneal cross-linking procedures.

Table of Contents

Patient Profile: Sarah's Keratoconus Journey

Sarah, a 28-year-old graphic designer from Chicago, noticed her vision deteriorating over 18 months despite new glasses. Her ophthalmologist diagnosed progressive keratoconus and recommended corneal cross-linking with Photrexa to halt the progression before she'd need a corneal transplant.

Her Challenge: Cigna initially denied coverage, citing "insufficient progression documentation." Like many patients, Sarah discovered that getting Photrexa approved requires specific evidence presented in a particular format.

Insurance Details:

  • Plan: Cigna PPO through her employer
  • Deductible: $2,500 (met)
  • Specialty drug coverage: Express Scripts/Accredo
  • Prior authorization required for procedures >$1,000

Pre-Authorization Preparation

Sarah's ophthalmologist, Dr. Martinez, gathered comprehensive documentation over two visits:

Required Clinical Evidence

Serial Corneal Topography (Essential):

  • Baseline Pentacam: Kmax 49.2 D (January 2023)
  • Follow-up Pentacam: Kmax 51.8 D (September 2023)
  • Progression: +2.6 D over 8 months (exceeds Cigna's ≥1.0 D threshold)

Supporting Documentation:

  • Pachymetry showing thinning from 465 μm to 445 μm
  • Visual acuity decline from 20/25 to 20/40 (best corrected)
  • Failed contact lens fitting notes
  • Family history of keratoconus
Clinician Corner: Cigna's MM-0141 Corneal Remodeling policy requires objective progression evidence. The ≥1.0 D Kmax increase standard comes from FDA iLink trials and is widely accepted by commercial payers.

Medical Necessity Letter Components

Dr. Martinez's letter addressed each Cigna criterion:

  1. Diagnosis: Progressive keratoconus, ICD-10 H18.621
  2. Progression Evidence: Specific Kmax values and dates
  3. Visual Impact: BCVA decline, contact lens intolerance
  4. Safety Parameters: Corneal thickness >400 μm post-epithelial removal
  5. FDA-Approved Protocol: Epithelium-off iLink system with Photrexa
  6. Prognosis: Risk of transplant without intervention

Submission Process

Step-by-Step Submission

1. Portal Access (Day 1) Dr. Martinez's staff accessed the Cigna Provider Portal and initiated a PA request for:

  • CPT 0402T (Corneal cross-linking)
  • Photrexa/Photrexa Viscous (riboflavin)

2. Documentation Upload (Day 2) Complete packet included:

  • Medical necessity letter (2 pages)
  • Serial topography reports (PDF)
  • Clinical notes from 3 visits
  • Visual acuity records
  • Contact lens trial documentation

3. Submission Confirmation (Day 3) PA request #CXL-2024-0892 submitted with all attachments. Cigna's standard review timeline: 5 business days.

Initial Outcome: The Denial

Day 8: Denial Letter Received

Cigna denied the request citing:

  • "Experimental/investigational treatment"
  • "Insufficient documentation of medical necessity"
  • Reference to outdated policy language

Common Denial Patterns: This reflects a frequent issue where Cigna's review process doesn't always align with their current coverage policies. The National Keratoconus Foundation notes that Cigna covers epithelium-off CXL, but initial denials often occur due to reviewer unfamiliarity.

The Appeal Strategy

Internal Appeal Level 1

Timeline: Filed within 180 days (Illinois requirement) Strategy: Address each denial reason systematically

Enhanced Documentation Package:

  • FDA Approval Evidence: Photrexa FDA approval letter and labeling
  • Updated Clinical Guidelines: American Academy of Ophthalmology recommendations
  • Peer-Reviewed Literature: 3 studies on CXL efficacy for progressive keratoconus
  • Policy Clarification: Quote from Cigna's MM-0141 supporting coverage

Peer-to-Peer Review: Dr. Martinez requested a peer-to-peer consultation with Cigna's medical director, highlighting:

  • FDA-approved indication alignment
  • Progressive nature preventing transplant
  • Standard-of-care status in ophthalmology
From Our Advocates: We've seen Cigna appeals succeed in 60-70% of cases when providers include specific Kmax progression data and cite the FDA approval directly. The key is addressing the "experimental" misconception with authoritative sources.

Appeal Outcome

Day 45: Level 1 appeal approved following peer-to-peer review.

Approval Terms:

  • Coverage for bilateral CXL (both eyes qualified)
  • In-network facility requirement
  • One-time treatment per eye
  • 90-day completion window

Resolution and Approval

Final Authorization Details:

  • Procedure approved at Northwestern Medicine
  • Photrexa covered under medical benefit (not pharmacy)
  • Patient responsibility: $500 copay per eye
  • Total procedure cost: $3,200 per eye

Treatment Timeline:

  • Right eye: Completed 3 weeks post-approval
  • Left eye: Scheduled 6 weeks later
  • Both procedures successful with no complications

What We'd Do Differently

Key Takeaways

1. Stronger Initial Documentation Include FDA approval references in the original PA to prevent "experimental" denials.

2. Proactive Peer-to-Peer Request medical director review with initial submission for complex cases.

3. Network Verification Confirm facility network status before PA submission to avoid delays.

4. Timeline Management Start PA process 4-6 weeks before desired treatment date to accommodate potential appeals.

Templates and Checklists

Pre-PA Checklist

  • Serial topography showing ≥1.0 D Kmax increase
  • Pachymetry demonstrating adequate thickness (>400 μm)
  • Visual acuity documentation
  • Contact lens trial records
  • Medical necessity letter addressing Cigna criteria
  • Provider network verification

Patient Phone Script for Cigna

"Hi, I'm calling to verify coverage for corneal cross-linking with Photrexa for progressive keratoconus. My member ID is [number]. Can you confirm:

  1. Is prior authorization required?
  2. Is my ophthalmologist Dr. [name] in-network for this procedure?
  3. What's my expected copay or coinsurance?
  4. Can you provide the current medical policy number?"

Counterforce Health helps patients and providers navigate these complex prior authorization processes, turning insurance denials into targeted, evidence-backed appeals with payer-specific workflows and clinical documentation requirements.

Illinois Appeals Process

Internal Appeals Timeline

Level Deadline to File Review Timeline Requirements
Level 1 180 days from denial 60 days Complete clinical documentation
Level 2 60 days from Level 1 denial 45 days Enhanced evidence, peer review

External Review Process

Illinois Health Carrier External Review Act provides independent physician review after exhausting internal appeals.

Key Requirements:

  • File within 30 days of final internal denial (shorter than many states)
  • Submit through Illinois Department of Insurance
  • Independent Review Organization (IRO) decision within 5 business days
  • Binding on Cigna if overturned

Emergency Contact:

  • Illinois DOI Consumer Hotline: (877) 527-9431
  • Illinois Attorney General Health Care Helpline: (877) 305-5145

When to Escalate

Contact Illinois regulators if:

  • Cigna misses appeal deadlines
  • Denial reasons contradict published policies
  • Provider network issues prevent access
  • Expedited review needed for vision-threatening progression

FAQ

Q: How long does Cigna PA take for Photrexa in Illinois? A: Standard review is 5 business days. Expedited review (72 hours) available if vision deterioration poses immediate risk.

Q: What if my ophthalmologist is out-of-network? A: Cigna may approve single case agreements for specialized CXL providers. Request this during PA submission with justification for specific expertise.

Q: Does step therapy apply to Photrexa? A: Generally no. Photrexa is FDA-approved specifically for progressive keratoconus with few therapeutic alternatives.

Q: Can I get coverage for epithelium-on cross-linking? A: No. Cigna only covers FDA-approved epithelium-off protocols with Photrexa.

Q: What if I need treatment in both eyes? A: Separate PAs typically required for each eye, though bilateral progression can strengthen medical necessity.

Q: How much does Photrexa treatment cost without insurance? A: Typical range $2,500-$4,000 per eye including facility, physician, and drug costs.

This guide is for educational purposes only and does not constitute medical or legal advice. Coverage decisions depend on individual plan benefits and clinical circumstances. For personalized assistance with Photrexa appeals, Counterforce Health provides specialized support for complex prior authorization cases.

Disclaimer: Insurance policies and requirements change frequently. Verify current information with Cigna and Illinois Department of Insurance before making coverage decisions. This information is current as of 2024 and may not reflect recent policy updates.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.